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Objective/Background: Cytomegalovirus (CMV) causes significant morbidity and mortality in
CMV seropositive patients undergoing umbilical cord blood transplants (UCBT). Our study aimed
to describe the incidence of CMV reactivation and burden of disease, as well as the tolerability
of an intensive prevention strategy as compared to historical prevention.
Methods: This was a retrospective chart review of 33 CMV seropositive patients that underwent
UCBT. The intensive prevention strategy in UCBT consisted of ganciclovir 5 mg/kg/d intra-
venously or valganciclovir 900 mg by mouth daily initiated at the beginning of the conditioning
regimen until Day 2. Then from Day 1 to Day +100, patients received valacyclovir 2 g by
mouth three times daily, and from Day +101 to Day +365, acyclovir 800 mg by mouth twice
daily. Historical standard prevention was acyclovir 800 mg by mouth twice daily initiated at
the beginning of the conditioning regimen until Day +365.
Results: Thirty-three patients were included from 2008 to 2014. There were no differences in
the adverse effects experienced between the two regimens (p = .4). CMV reactivation occurredas City, KS
106 M. Rinehart et al.significantly later with intensive prevention (p = .003). The median CMV viral titer at reactiva-
tion was lower in the intensive versus the historic prevention (1,800 copies/mL and
2,700 copies/mL, respectively), but was not significantly different. CMV disease occurred sig-
nificantly less often in the intensive group (p = .039).
Conclusion: The results from this study indicate that the intensive prevention strategy was well
tolerated, significantly delayed CMV reactivation, and patients had less CMV disease.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Cytomegalovirus (CMV), a member of the herpes virus fam-
ily, is a ubiquitous environmental virus affecting roughly
50–85% of adults in the United States [1]. Once exposed
to CMV, the host becomes a lifelong carrier, as the virus
enters a dormant state within cells and evades detection
and clearance by the immune system. CMV is a known cause
of significant morbidity and mortality in CMV seropositive
patients that undergo hematopoietic stem cell transplanta-
tion, but it is especially dangerous in umbilical cord blood
transplants (UCBT). This is due to longer engraftment times,
which render patients susceptible to the development of
significant infectious complications [1–4]. CMV reactivation
is most likely to occur during the first 100 days of the trans-
plant course, but can also occur as late as 1 year later [1].
Reactivation of the latent virus during immunosuppression
may lead to detectable viremia and progress to CMV
diseases, such as pneumonia or gastritis. Rarely, CMV
reactivation causes hepatitis, retinitis, encephalitis, or even
graft failure [1]. Seropositive CMV patients that do not
receive prophylaxis against reactivation have reactivation
rates between 70% and 100% after UCBT [1–3].
The literature available is limited regarding optimal pro-
phylaxis for CMV seropositive patients undergoing UCBT.
There has been only one study by Milano et al. [11] pub-
lished in 2011. In this study, patients underwent either a
standard or intensive prevention strategy. The medications
and timing of administration of these agents can be seen in
Table 1. CMV screening in the intensive cohort was per-
formed more frequently and earlier post-transplant, with
a lower threshold to begin preemptive therapy than in the
standard prophylaxis group. The intensive strategy resulted
in a statistically significant reduction in the hazard ratio for
CMV reactivation, cases of CMV disease by the end of year 1
post-transplant, and fewer days on CMV-specific antiviral
therapy [11].
After the publication of this study in 2011, our institu-
tion, the University of Kansas Hospital (UKH; KS, USA),
developed a similar intensive prevention strategy for CMV
seropositive patients undergoing UCBT. The regimen and
monitoring parameters are further described in the ‘‘Mate-
rials and methods” section and can be seen in Table 1. This
report includes a review of safety and efficacy outcomes for
patients treated using this intensive strategy.
The main purpose of this retrospective study was to eval-
uate the tolerability and adverse effects associated with the
intensive prevention strategy adopted by our institution.
The secondary outcomes evaluated included the incidenceof CMV reactivation and disease in seropositive UCBT
patients after implementation of the intensive strategy.
The findings of this study will add to the current knowledge
base, as there is limited data concerning CMV prevention
during UCBT in seropositive patients.
Materials and methods
This was a retrospective chart review of 33 patients who
underwent UCBT at the UKH. The study was approved by
the UKH Institutional Review Board. Patients that received
the intensive prevention strategy (December 2011–Decem-
ber 2014; n = 16) were compared with patients who received
the standard regimen (January 2008–November 2011;
n = 17). Patients who underwent UCBT during this period
were retrospectively identified and screened for inclusion.
Patients were followed from the beginning of the prepara-
tive regimen until Day +365 or until the patient was lost
to follow-up or death. Patients P17 years of age, CMV
seropositive prior to UCBT, and who had received prophy-
laxis for CMV were included in the study. Patients were
excluded if they had received prior anti-CMV therapy or
were CMV seronegative prior to UCBT.
The intensive prevention strategy for CMV seropositive
patients was ganciclovir 5 mg/kg/d intravenously or valgan-
ciclovir 900 mg by mouth daily initiated at the beginning of
conditioning until Day2. From Day1 to Day +100, patients
received valacyclovir 2 g bymouth three times daily and from
Day +101 to Day +365, patients received acyclovir 800 mg by
mouth twice daily. Prior to the initiation of this intensive pre-
vention strategy in December 2011, patients received the
standard prevention of acyclovir 800 mg bymouth twice daily
from the beginning of the conditioning regimen until Day
+365. CMV monitoring was completed biweekly via poly-
merase chain reaction (PCR) from Day +20 until Day +100,
then weekly until Day +365. PCR testing was performed with
Luminex MultiCode CMV reagents (Luminex, Austin, TX, USA)
and a Roche LightCycler CMV Quant Kit (Roche, Basel,
Switzerland). CMV DNA levels were considered positive upon
reaching 300 copies/mL. Levels between 300 copies/mL and
499 copies/mL were reported as <500 copies/mL. Once
levels were P500 copies/mL, levels were reported in
100 copies/mL intervals. Renal toxicity was defined as a
serum creatinine increase ofP0.5 mg/dL.
Statistical analysis
Categorical data was analyzed using either Fisher’s exact
test or Pearson’s chi-square test where appropriate and
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Cytomegalovirus in umbilical cord transplants 107for continuous data, Student t test was utilized. Results
were considered significant at the 5% critical level
(p < .05). Descriptive statistics were also utilized where
appropriate.Results
There were a total of 33 patients included in this retrospec-
tive chart review that were CMV seropositive before under-
going UCBT. Standard prophylaxis was received by 17
patients, while intensive prevention was received by 16
patients. Baseline patient and disease characteristics are
presented in Table 2. Patients in both groups were compa-
rable in age, sex, and primary disease. Table 3 shows the
umbilical cord blood transplant characteristics, including
number of cords received and human leukocyte antigen
disparity, conditioning-regimen intensity, and time to
engraftment, all of which were similar between groups.
The primary endpoint of tolerability was shown to be
similar between the standard and intensive prevention reg-
imens (Table 4) and renal toxicity was the most common
adverse event for both regimens. The next most common
adverse event was a decrease in the white blood cell count
and absolute neutrophil count but there was no difference
in time to engraftment. The remaining adverse event docu-
mented was delayed engraftment with standard acyclovir
prophylaxis.
CMV resistance was documented in two instances. The
first case occurred in a patient with viremia, which was
found to be resistant to valganciclovir and ganciclovir.
The other case occurred in a patient with CMV retinitis.
The CMV viral titer for this patient continued to rise while
receiving 2 weeks of foscarnet treatment. Treatment was
changed to a combination of ganciclovir and cidofovir while
resistance testing was in progress. Testing showed that
there was resistance to ganciclovir and cidofovir; however,
the patient responded to this treatment combination. One
possible explanation was that there may have been two
separate strains of the virus.
Secondary endpoints included the incidence of CMV reac-
tivation and disease in seropositive UCBT patients after
implementation of the intensive prevention strategy
(Table 5). Overall CMV reactivation was not significantly dif-
ferent between the two groups (p = .39). The viral load at
the time of CMV reactivation and the number of days trea-
ted when CMV reactivation occurred were not significantly
different between the two prevention strategies (p = .21
and p = .24, respectively). Twice as many patients, four
compared to two, experienced no CMV reactivation in the
intensive prophylaxis regimen, and early reactivation was
significantly decreased in the intensive regimen (p = .007).
The time during which CMV was reactivated was found to
be significantly delayed in the intensive prevention group
(from 40 days to 89 days; p = .003). The two patients under-
going the standard prevention strategy that did not experi-
ence CMV reactivation both passed away before Day +365.
One passed away on Day +13 before PCR monitoring started
and the other at Day +72. Of the four patients undergoing
the intensive prevention strategy that that did not reacti-
vate, one passed away at Day +68, one transferred care to
another hospital near their home and was lost to follow-
Table 2 Patient and disease demographics.
Standard prevention, n = 17 (%) Intensive prevention, n = 16 (%) p
Median age, y (IQR) 49 (44–64) 45 (29–57) .067
Sex .88
Male 10 (59) 9 (56.3)
Female 7 (41) 7 (43.7)
Primary disease .286
Acute myelogenous leukemia 13 (76.5) 9 (56.3)
Acute lymphocytic leukemia 3 (17.6) 3 (18.7)
Myelodysplastic syndrome 1 (5.9) —
Chronic lymphocytic leukemia — 2 (12.5)
Hodgkin’s lymphoma — 1 (6.25)
Non-Hodgkin’s lymphoma — 1 (6.25)
Note. IQR = interquartile range.
Table 3 Umbilical cord blood and preparative regimen characteristics.
Standard prevention, n = 17 (%) Intensive prevention, n = 16 (%) p
No. of donors .085
1 2 (11.8) 6 (37.5)
2 15 (88.2) 10 (62.5)
Human leukocyte antigen disparity a .675
4/6 10 (58.8) 7 (43.75)
5/6 6 (35.3) 8 (50)
6/6 1 (5.9) 1 (6.25)
Regimen intensity .619
Myeloablative 6 (35.3) 7 (43.7)
Non-myeloablative 11 (64.7) 9 (56.3)
Time to engraftment, days (median) 26 24 .089
a Human leukocyte antigen matching reflects the least matched number if two cords were received.
Table 4 Adverse Effects of CMV Prevention Therapy.
Standard prevention, n = 17 (%) Intensive prevention, n = 16 (%) p
Adverse effects 9 (53) 4 (25) .4
Renala 5 (29.5) 2 (12.5)
Otherb 4 (23.5) 2 (12.5)
Resistance 2 (11.8) —
Note. CMV = cytomegalovirus.
a Renal = serum creatinine increase P0.5 mg/dL.
b Other = toxicity requiring dose adjustments or a change to a different medication.
108 M. Rinehart et al.up at Day +273, one passed away at Day +893, and the fourth
patient is still alive at Day +379.
CMV disease was found to occur significantly less with the
intensive strategy as compared to standard prevention
(p = .039). The standard prevention group had a total of
seven patients with CMV disease, consisting of five cases
of pneumonia, one case of enteritis, and one case of retini-
tis. The intensive prevention group only had one case of
CMV enteritis. Of the 15 patients in the standard prevention
group that had CMV reactivation, eight had isolated viremawithout disease, while the intensive prevention group
tended to only developed virema without disease. Eleven
out of 12 patients experiencing reactivation developed
isolated viremia. One patient undergoing standard preven-
tion strategy passed away due to biopsy-proven CMV
pneumonia.
The cumulative incidence of CMV reactivation in both the
intensive and standard prevention strategies over the
course of the study period is shown in Fig. 1. The reactiva-
tion time was delayed, but tended to follow the same
Table 5 CMV reactivation and disease data.
Standard prevention, n = 17 Intensive prevention, n = 16 p
Reactivation
Early (Day 0 to Day +100) 15 7 .007
Late (Day +101 to Day +365) — 5
Reactivation .39
Any (Day 0 to Day +365) 15 12
No (Day 0 to Day +365) 2 4
Time to 1st reactivation, days (mean) 40 89 .003
Viral load at reactivation, copies/mL (mean) 2,773 1,866 .21
Days of treatment (mean) 34 26.4 .24
CMV Disease a .039
Disease 7 1
No Disease 10 15
Death due to CMV Disease b 1 —
All-cause mortality at 1 year .61
Alive 10 8
Deceased 7 8
Note. CMV = cytomegalovirus.
a Pneumonitis, enteritis, retinitis.
b Pneumonia.
Figure 1 Incidence of CMV reactivation. Note. CMV = cytomegalovirus.
Cytomegalovirus in umbilical cord transplants 109reactivation rate until around Day +60. Following this, all
remaining patients still alive in the standard prevention
group reactivated by Day +100, while the intensive preven-
tion group plateaued until late reactivation at Day +140.
From Day +159 onward, the three remaining intensive pre-
vention patients experienced no reactivation.
The all-cause mortality of patients depicted over the
study period is shown in Fig. 2. As reported in Table 5, there
was no difference in the overall survival of patients between
the two prevention strategies at 1 year.Discussion
The intensive prevention strategy was well tolerated by
patients as compared to standard prevention. Adverse
effects were mainly limited to renal toxicity during
prevention, followed by a reduced white blood cell count,absolute neutrophil count, or delayed engraftment during
CMV-preemptive treatment, but were not significantly
different than what was observed in the standard preven-
tion strategy.
While there was not an overall decrease in CMV reactiva-
tion between the two prevention strategies due to the small
population size, there was a significant decrease in early
reactivation (from Day 0 to Day +100), and the mean reacti-
vation time was significantly delayed, from 40 days to 89
days. Perhaps there would have been a difference in the
overall reactivation rate had the two patients in the
standard prevention study survived until Day +100, as all
standard prevention patients had reactivated by Day +100.
One patient passed away at Day +13 before PCR monitoring
occurred, and the other at Day +72.
Patients in the standard prevention group began to have
CMV reactivation around the time of engraftment. Approxi-
mately 25% of these patients had CMV reactivation before
Figure 2 Patient survival post-transplant.
110 M. Rinehart et al.engraftment, which occurred at a median of 26 days. Reac-
tivation in the intensive prevention group began to occur
around Day +40, about 2 weeks after the median engraftment
time. This significant delay in CMV reactivation observed in
the intensive prevention regimen potentially allows the UCBT
recipient time to develop a more functional immune system
to help fight CMV reactivation and disease [12]. It is difficult
to determine the drug that led to this delay in reactivation
(ganciclovir or valacyclovir in the intensive prevention strat-
egy). Ganciclovir has an enhanced ability to prevent CMV
replication as compared to acyclovir. However, using high-
dose valacyclovir may also lead to sufficient concentrations
that may also effectively inhibit CMV replication, which
low-dose acyclovir may not be able to achieve.
The consequences of CMV reactivation, whether early or
late during the transplant process, cannot be overesti-
mated. CMV reactivation in the late setting has the poten-
tial to cause graft failure, expose patients to antivirals
having significant toxicities, require admission for close
patient monitoring, and potentially lead to patient death.
Delaying CMV reactivation to the late period (Day +100
onward) is a desired goal in UCBT for several reasons. UCB
is inherently devoid of mature immune cells, specifically T
cells, and therefore, takes longer to develop the immune
system response necessary to fight CMV reactivation or dis-
ease. The CD8+ T cells begin to recover around Day +45 to
Day +100, while CD4+ T cells recover more slowly, typically
around Day +100 to Day +365. T cells are needed to effec-
tively combat CMV reactivation, so any prophylaxis that
can delay or prevent this reactivation to the late setting
in UCBT recipients is desirable.
There were several important secondary outcomes mea-
sured, but none more important than CMV disease. Results
showed a significant decrease in CMV disease with the
intensive prevention strategy, from 41% to 6.3%, which
was similar to that of previously published data. These
results are likely due to the utilization of a more potent
anti-CMV therapy in ganciclovir early during the preparative
regimen, as well as high-dose valacyclovir. Singling out one
specific agent as the sole cause of this is beyond the scope
of this study and would require further investigation.There were several drugs that were part of the intensive
prevention strategy. The main difference between the
intensive prevention strategy implemented by Milano
et al. [11] and our institution was the utilization of acyclovir
at UKH from Day +101 to Day +365, while Milano et al. [11]
utilized valganciclovir. The reason our institution did not
utilize valganciclovir was due to the potential effects on
engraftment and for graft dysfunction. In our study, there
was an increase in CMV reactivation in the intensive preven-
tion group after Day +101, following transition from valacy-
clovir to acyclovir, that could have potentially been due to
changing agents. Perhaps extension of valacyclovir from Day
+101 to Day +200 could be implemented, as the second peak
of CMV reactivation in our group occurred from Day +140 to
Day +160. Incorporation of valganciclovir prophylaxis during
this time frame could also be trialed, but there is inherent
risk of developing ganciclovir-resistant CMV viremia or
disease and losing a valuable resource in an area with few
effective treatment options.
Overall, our study only had one patient die from CMV,
and this was a member of the standard prophylaxis cohort.
This patient had CMV pneumonia diagnosed via bronchoalve-
olar lavage at Day +74 and passed away on Day +86, despite
adequate therapy. This study was not powered to determine
an impact on overall survival. The study by Milano et al. [11]
also did not show a difference in overall survival during the
first 100 days after transplant or at 1 year.
There were some limitations with this study. First, there
were two patients that were initiated onto the standard
prevention regimen and were later transitioned over to
the intensive prevention regimen after protocol implemen-
tation in December 2011. One patient received 6 days of
standard prophylactic acyclovir and the other patient
received 26 days of the same treatment before being tran-
sitioned over to valacyclovir. Both patients were included
in the intensive prevention regimen for purposes of the
analysis but had less than the full intensive prevention
regimen due to the timing of transplant. One patient did
have CMV reactivation at Day +159, while the other never
experienced reactivation. We also recognized the inherent
limitations that occurred due to the retrospective nature
Cytomegalovirus in umbilical cord transplants 111of this study and the small sample size of CMV seropositive
patients. Another limitation of this study was related to
patient follow-up, as many patients traveled great distances
from rural settings to receive care at our institution and
may have followed-up post-transplant closer to home or at
another institution.
A new anti-CMV medication, letermovir, is currently
undergoing a Phase 3 clinical trial. Letermovir showed effi-
cacy in reducing the incidence of CMV infections in recipi-
ents of allogeneic hematopoietic cell transplants when
compared to placebo and has an acceptable safety profile
[14]. If approved, this agent could be incorporated into an
intensive prevention strategy or compared alone against
an intensive prevention strategy.
Conclusion
In conclusion, the intensive prevention strategy imple-
mented by the UKH was well tolerated as compared to the
standard prevention strategy. The intensive regimen
showed statistical significance in delaying CMV reactivation,
along with a reduction in CMV disease occurrence. These
results provide additional evidence supporting the imple-
mentation of an intensive prevention strategy in CMV
seropositive UCBT recipients.
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